Key result
AJW200 provided sustained inhibition of platelet aggregation for up to 2 weeks without extensive prolongation of bleeding time compared to abciximab in cynomolgus monkeys.
Why the study?
Does AJW200 inhibit platelet aggregation without extensive bleeding time prolongation in cynomolgus monkeys and human platelets?
Does AJW200 inhibit platelet aggregation without extensive bleeding time prolongation in cynomolgus monkeys and human platelets?
Answers are grounded in this paper and cite their sources.
AJW200 provides sustained antiplatelet effects via glycoprotein Ib-vWF blockade without extensive bleeding time prolongation, likely due to its shear-stress-dependent inhibitory action.
The interaction between platelet glycoprotein Ib and von Willebrand factor (vWF) plays a crucial role in platelet-mediated thrombus formation under high-shear-stress conditions. The aim of this study was to investigate the antiplatelet profile of a humanized anti-vWF monoclonal antibody, AJW200. In vitro studies were performed with a modified cone-and-plate viscometer and human platelets. AJW200 inhibited high-shear-stress-induced platelet adhesion, aggregation, and thrombin generation, but it did not have such effects under low-shear-stress conditions. Although abciximab inhibited platelet aggregation under both shear stress conditions, it did not inhibit platelet adhesion and thrombin generation. In addition, the pharmacokinetics and pharmacodynamics of AJW200 were evaluated in cynomolgus monkeys. Sustained inhibition of ristocetin-induced platelet aggregation was observed over 24 hours, 6 days, and 2 weeks after a single bolus injection of 0.3, 1, and 3 mg/kg, respectively. Moderate prolongation of the bleeding time was observed at the doses of 1 and 3 mg/kg. Abciximab markedly prolonged the bleeding time at 0.4 mg/kg, at which concentration complete inhibition of ADP-induced platelet aggregation was observed. These results suggest that glycoprotein Ib-vWF blockade with AJW200 results in a sustained antiplatelet effect without extensive prolongation of the bleeding time, probably due to a shear-stress-dependent inhibitory action.
No takes yet. Share an insight, caveat, or question.
Kageyama et al. (2002) studied this question. AJW200 vs. Abciximab was evaluated on Platelet aggregation and bleeding time. AJW200 provided sustained inhibition of platelet aggregation for up to 2 weeks without extensive prolongation of bleeding time compared to abciximab in cynomolgus monkeys.
Synapse has enriched 10 related papers. Consider them for comparative context: